Abstract
Although adenovirus is an attractive vehicle for transferring therapeutic genes in vivo, animal studies have indicated that the clinical usefulness of adenoviruses may be limited by their immunogenicity. Although immunosuppressive strategies around the time of initial exposure of adenoviruses have been shown to prevent the formation of neutralizing antibodies and permit the successful readministration of adenoviruses in animals, the practicality of the approaches remains questionable. Because the majority of prospective gene therapy patients have already been infected with wild-type adenoviruses, initial treatment with adenoviruses in humans may correspond to readministration of adenoviruses into animals. It is shown here that although intraportal infusion of adenoviruses carrying a reporter lacZ gene resulted in transient high levels of transgene expression in the rat liver, intraportal readministration of adenoviruses failed to induce detectable levels of transgene expression. Conversely, when animals were treated transiently with cyclophosphamide before the intraportal readministration of adenoviruses, development of neutralizing antibodies and antigen-specific T cell proliferation in response to adenoviral readministration was significantly suppressed and successful re-expression of the transgene was achievable. These results may have important implications for efficacy considerations when adenoviral vectors are employed in clinical settings.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Strauss SE . Adenovirus infections in humans. In: Ginsberg HS (ed) . The Adenoviruses Plenum Press: New York 1984 451–496
Rosenfeld MA et al. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium Cell 1992 68: 143–155
Zabner J et al. Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis Cell 1993 75: 207–216
Crystal RG et al. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis Nat Genet 1994 8: 42–51
Stratford-Perricaudet LD et al. Evaluation of the transfer and expression in mice of an enzyme-encoding gene using a human adenovirus vector Hum Gene Ther 1990 1: 241–256
Jaffe H . Adenovirus-mediated in vivo gene transfer and expression in normal rat liver Nature 1992 1: 372–378
Kay MA et al. In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs Proc Natl Acad Sci USA 1994 91: 2353–2357
Ishibashi S et al. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery J Clin Invest 1993 92: 883–893
Kozarsky KF et al. In vivo correction of low density lipoprotein receptor deficiency in the Watanabe Heritable hyperlipidemic rabbit with recombinant adenoviruses J Biol Chem 1994 269: 13695–13702
Tripathy SK, Black HB, Goldwasser E, Leiden JM . Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors Nature Med 1996 2: 545–550
Yang Y, Li Q, Ertl HCJ, Wilson JM . Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses J Virol 1995 69: 2004–2015
Kaplan JM et al. Humoral and cellular immune responses of nonhuman primates to long-term repeated lung exposure to Ad2/CFTR-2 Gene Therapy 1996 3: 117–127
Fang B et al. Lack of persistence of E1-recombinant adenoviral vectors containing a temperature-sensitive E2A mutation in immunocompetent mice and hemophilia B dogs Gene Therapy 1996 3: 217–222
Dai Y et al. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression Proc Natl Acad Sci USA 1995 92: 1401–1405
Engelhardt JF, Ye X, Doranz B, Wilson JM . Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver Proc Natl Acad Sci USA 1994 91: 6196–6200
Yang Y et al. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy Proc Natl Acad Sci USA 1994 91: 4407–4411
Yei S et al. Adenovirus-mediated gene transfer for cystic fibrosis: quantitative evaluation of repeated in vivo vector administration to the lung Gene Therapy 1994 1: 192–200
Dong J-Y et al. Systematic analysis of repeated gene delivery into animal lungs with a recombinant adenovirus vector Hum Gene Ther 1996 7: 319–331
Ilan Y et al. Oral tolerization to adenoviral proteins permits repeated adenovirus-mediated gene therapy in rats with pre-existing immunity to adenoviruses Hepatology 1998 27: 1368–1376
Yang Y, Trinchieri G, Wilson JM . Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung Nature Med 1995 1: 890–893
Weinberg A et al. Enzyme linked immunosorbent assay: determination of anti-adenovirus antibodies in an infant population Rev Inst Med Trop São Paulo 1989 31: 336–340
Rosenecker J et al. Adenovirus infection in cystic fibrosis patients: implication for the use of adenoviral vectors for gene transfer Infection 1996 24: 5–8
Kuriyama S et al. Inhibitory effects of human sera on adenovirus-mediated gene transfer into rat liver Anticancer Res 1998 18: 2345–2352
Vilquin J-T et al. FK506 immunosuppression to control the immune reactions triggered by first generation adenovirus-mediated gene transfer Hum Gene Ther 1995 6: 1391–1401
Jooss K, Yang Y, Wilson JM . Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung Hum Gene Ther 1996 7: 1555–1566
Smith TAG et al. Transient immunosuppression permits successful repetitive intravenous administration of an adenovirus vector Gene Therapy 1996 3: 496–502
Ilan Y et al. Transient immunosuppression with FK506 permits long-term expression of therapeutic genes introduced into the liver using recombinant adenoviruses in the rat Hepatology 1997 26: 949–956
Lei D et al. Nondepleting anti-CD4 antibody treatment prolongs lung-directed E1-deleted adenovirus-mediated gene expression in rats Hum Gene Ther 1996 7: 2273–2279
Scaria A et al. Antibody to CD40 ligand inhibits both humoral and cellular immune responses to adenoviral vectors and facilitates repeated administration to mouse airway Gene Therapy 1997 4: 611–617
Yang Y et al. Transient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissues J Virol 1996 70: 6370–6377
Kay MA et al. Transient immunomodulation with anti-CD40 ligand antibody and CTLA4Ig enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver Proc Natl Acad Sci USA 1997 94: 4686–4691,
Jooss K, Turka LA, Wilson JM . Blunting of immune responses to adenoviral vectors in mouse liver and lung with CTLA4Ig Gene Therapy 1998 5: 309–319
Weiss A . T lymphocyte activation. In: Paul WE (ed) . Fundamental Immunology Raven Press: New York 1993 467–504
Kaplan JM, Smith AE . Transient immunosuppression with deoxyspergualin improves longevity of transgene expression and ability to readminister adenoviral vector to the mouse lung Hum Gene Therapy 1997 8: 1095–1104
Wang Q et al. Persistent transgene expression in mouse liver following in vivo gene transfer with a ΔE1/ΔE4 adenovirus vector Gene Therapy 1997 4: 393–400
Nakamura Y et al. Adoptive immunotherapy with murine tumor-specific T lymphocytes engineered to secrete interleukin 2 Cancer Res 1994 54: 5757–5760
Niwa H, Yamamura K, Miyazaki J . Efficient selection for high-expression transfectants with a novel eukaryotic vector Gene 1991 108: 193–200
Miyake S et al. Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full-length virus genome Proc Natl Acad Sci USA 1996 93: 1320–1324
Graham FL, Prevec L . Manipulation of adenovirus vectors. In: Murray EJ (ed) . Methods in Molecular Biology Humana Press: Clifton 1991 109–128
Kuriyama S et al. A potential approach for gene therapy targeting hepatoma using a liver-specific promoter on a retroviral vector Cell Struct Funct 1991 16: 503–510
MacGregor GR et al. Use of E. coli lac Z (β-galactosidase) as a reporter gene. In: Murray EJ (ed) . Methods in Molecular Biology Humana Press: Clifton 1991 217–235
Yang Y, Greenough K, Wilson JM . Transient immune blockade prevents formation of neutralizing antibody to recombinant adenovirus and allows repeated gene transfer to mouse liver Gene Therapy 1996 3: 412–420
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kuriyama, S., Tominaga, K., Kikukawa, M. et al. Transient cyclophosphamide treatment before intraportal readministration of an adenoviral vector can induce re-expression of the original gene construct in rat liver. Gene Ther 6, 749–757 (1999). https://doi.org/10.1038/sj.gt.3300894
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3300894
Keywords
This article is cited by
-
Recent progress in the battle between oncolytic viruses and tumours
Nature Reviews Cancer (2005)
-
Increased revascularization efficacy after administration of an adenovirus encoding VEGF121
Gene Therapy (2004)
-
Particle-mediated gene transfer into murine livers using a newly developed gene gun
Gene Therapy (2000)
